Skip to main content

News & Publications

2024

Persistence Rates of Second-Line Biologics in Psoriasis Following First-Line Biologic Treatment Based on Nationwide Data From Greece

2024

Cost-Effectiveness Analysis of Bimekizumab in Patients With Active Psoriatic Arthritis (PsA) in Greece

2024

Productivity Loss and Indirect Cost Related to Atopic Dermatitis in Greece

2024

Patients’ Journey and Burden of Disease Among Axial Spondyloarthritis Patients in Greece: A Cross-Sectional Online Survey

2024

Budget Impact Analysis of Empagliflozin for Adults With Chronic Kidney Disease (CKD) in Greece

2024

Budget Impact Analysis of Bimekizumab for the Treatment of Axial Spondyloarthritis (axSpA) in Greece

2024

Cost of Biologics in Patients Suffering From Psoriasis in Greece: A Retrospective Longitudinal Cohort Study

2024

Patients’ Journey and Burden of Disease Among Psoriatic Arthritis Patients in Greece: A Cross-Sectional Online Survey

2024

Budget Impact Analysis of Ivosidenib in Combination With Azacitidine for the Treatment of Previously Untreated mIDH1 Positive Acute Myeloid Leukaemia (AML) Patients, Ineligible for Intensive Induction Chemotherapy in Greece

2024

Cost-Effectiveness Analysis of Bimekizumab in Patients With Axial Spondyloarthritis (AxSpA) in Greece

2024

Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in Greece

2024

Budget Impact Analysis of Bimekizumab for the Treatment of Active Psoriatic Arthritis (PsA) in Greece

2024

Cost-Effectiveness Analysis of Empagliflozin for Adults With Chronic Kidney Disease (CKD) in Greece

2024

Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for the Treatment of Moderate-to-Severe Active Crohn's Disease in Greece

2024

Analysis of circulating miRNA expression profiles and machine learning models associated with response to irinotecan-based therapy in metastatic colorectal cancer

2022

Budget Impact Analysis of Bimekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Greece

2022

Cost-Effectiveness of Brexucabtagene Autoleucel (Brexu-cel, CAR-T) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma in Greece

2022

Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece

2022

Cost-Effectiveness Analysis of Bimekizumab in Patients With Moderate-to-Severe Plaque Psoriasis in Greece

2022

A Budget Impact Analysis of Introducing a New Combination of Atorvastatin and Ezetimibe in Greece

2022

Budget Impact Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

2022

Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

2022

Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL

2021

Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting

2020

The Cost-Effectiveness of Liposomal Irinotecan and 5-Fluorouracil (5-FU)/ Leucovorin (LV) for the Treatment of Patients with Metastatic Adenocarcinoma of Pancreas WHO Have Progressed Following the Use of Gemcitabine-Related Therapies in Greece

2020

Budget Impact Analysis of Trifluridine/Tipiracil As a 3-Line Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients Who Have Received at Least Two Prior Therapies for Metastatic Disease in Greece.

2020

Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-Small-Cell-Lung Cancer in Greece

2020

Cost Comparison of Low Dose Dabigatran over Other NOVEL ORAL Anticoagulants for the Treatment of Patients with NON-Valvular Atrial Fibrillation WHO HAD NOT Previously Taken an ORAL Anticoagulant in Greece

2020

Cost-Effectiveness of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Disease

2020

Budget Impact Analysis of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and High Risk or Established Atherosclerotic Cardiovascular Disease in Greece

2019

Does a standard Willingness-to-pay thereshold exist in Greece?

2019

End-of-LIFE Cost for Lung Cancer Patients in Greece: A hospital-based retrospective study

2019

Incidence and Cost of Bleeding events requiring Hospitalization in patients with Atrial Fibrillation treated with Acenocoumarol, in Greece

2019

Budget Impact Analysis of a Biosynthetic MESH for abdominal Wall Hernia repair in Complex Hernias in Greece

2019

Real-World Data of Nivolumab in Non-Small Cell Lung Cancer patients in Greece

2019

Budget Impact Analysis of Damoctocog Alfa Pegol in Severe Hemophilia A in Greece

2019

Real-World Data for Non Small Cell Lung Cancer patients with positive EGFR Mutation in Greece: Preliminary Results from a registry

2019

Cost-effectiveness analysis of Tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece

2019

Cost-minimization Analysis of Damoctocog Alfa Pegol in severe Hemophilia A in Greece